Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Deepak M W BalakY José Manuel CarrascosaStamatis GregoriouPiergiacomo Calzavara-PintonAnthony BewleyJoana AntunesMartin E NyelandMarta G ViolaLaura M SawyerLidia BeclaPublished in: The Journal of dermatological treatment (2020)
Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population.